Literature DB >> 26791968

Analysis and comparison of statin prescription patterns and outcomes according to clinical department.

H-S Kim1,2, H Kim3, H Lee4, B Park1,5, S Park1,5, S-H Lee2, J H Cho2, H Song6, J H Kim7, K-H Yoon1,2, I Y Choi1.   

Abstract

WHAT IS KNOWN AND
OBJECTIVE: There is a disparity between the Korean treatment guidelines and actual clinical prescription habits. This study was designed to evaluate the department-specific disparities and achievement rates for low-density lipoprotein cholesterol (LDL-C) targets, based on each department's specific statin prescription patterns.
METHODS: We retrospectively evaluated data from 31 718 patients who had been prescribed a statin at least once between January 2008 and June 2013 at our institution. Patients were classified into the high-risk (target LDL-C < 100 mg/dL) or moderate-risk (target LDL-C < 130 mg/dL) groups, according to the National Cholesterol Education Programme-Adult Treatment Panel III guidelines. RESULTS AND DISCUSSION: Statins were most commonly prescribed in the cardiology (32·0%) and endocrinology (26·6%) departments. For the high-risk group, 70% of patients in the cardiology, endocrinology and cardiac surgery departments achieved their target LDL-C levels (<100 mg/dL). However, the target achievement rates in most other departments were <70%. For the moderate-risk group, 79·2% of patients achieved their target levels. Departments that prescribed a greater number of high- or intermediate-potency statins were more likely to achieve their target LDL-C levels. The group that achieved their target LDL-C levels (<100 mg/dL) exhibited a significant positive relationship (Spearman's correlation coefficient = 0·8571, P = 0·0065), from low to high potency. WHAT IS NEW AND
CONCLUSION: Some departments tend to undertreat when prescribing statins. However, to reach to the target LDL-C levels, physicians must overcome their tendency to undertreat with statins. We believe that the target achievement rate will increase if doctors are more actively aware of a patient's individual status and related risk factors before prescribing statins.
© 2016 John Wiley & Sons Ltd.

Entities:  

Keywords:  HMG-CoA reductase inhibitor (statin); Hypercholesterolaemia; LDL-cholesterol; target achievement rate; treatment gap

Mesh:

Substances:

Year:  2016        PMID: 26791968     DOI: 10.1111/jcpt.12350

Source DB:  PubMed          Journal:  J Clin Pharm Ther        ISSN: 0269-4727            Impact factor:   2.512


  7 in total

1.  Pilot Algorithm Designed to Help Early Detection of HMG-CoA Reductase Inhibitor-Induced Hepatotoxicity.

Authors:  Joo Young Hong; Hun-Sung Kim; In Young Choi
Journal:  Healthc Inform Res       Date:  2017-07-31

2.  Development of Clinical Data Mart of HMG-CoA Reductase Inhibitor for Varied Clinical Research.

Authors:  Hun Sung Kim; Hyunah Kim; Yoo Jin Jeong; Tong Min Kim; So Jung Yang; Sun Jung Baik; Seung Hwan Lee; Jae Hyoung Cho; In Young Choi; Kun Ho Yoon
Journal:  Endocrinol Metab (Seoul)       Date:  2017-02-28

3.  Developing a multi-center clinical data mart of ACEI and ARB for real-world evidence (RWE).

Authors:  Hun-Sung Kim; Sue Hyun Lee; Tong Min Kim; Ju Han Kim
Journal:  Clin Hypertens       Date:  2018-12-15

4.  Real-world Evidence versus Randomized Controlled Trial: Clinical Research Based on Electronic Medical Records.

Authors:  Hun-Sung Kim; Suehyun Lee; Ju Han Kim
Journal:  J Korean Med Sci       Date:  2018-06-26       Impact factor: 2.153

5.  Achievement of the low-density lipoprotein cholesterol goal among patients with dyslipidemia in South Korea.

Authors:  Siin Kim; Sola Han; Pratik P Rane; Yi Qian; Zhongyun Zhao; Hae Sun Suh
Journal:  PLoS One       Date:  2020-01-30       Impact factor: 3.240

Review 6.  Data Pseudonymization in a Range That Does Not Affect Data Quality: Correlation with the Degree of Participation of Clinicians.

Authors:  Soo-Yong Shin; Hun-Sung Kim
Journal:  J Korean Med Sci       Date:  2021-11-15       Impact factor: 2.153

7.  Phenotyping of Korean patients with better-than-expected efficacy of moderate-intensity statins using tensor factorization.

Authors:  Jingyun Choi; Yejin Kim; Hun-Sung Kim; In Young Choi; Hwanjo Yu
Journal:  PLoS One       Date:  2018-06-13       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.